DIA496.13+0.22 0.04%
SPY737.62+6.04 0.83%
QQQ711.23+16.29 2.34%

iBio names Elizabeth Stoner to board as Schimmelpennink steps down

PUBT·05/08/2026 11:15:22
Listen to the news
iBio names Elizabeth Stoner to board as Schimmelpennink steps down
  • iBio appointed Elizabeth Stoner, M.D., M.S. to board as independent director.
  • Stoner also joined Compensation Committee; Eef Schimmelpennink stepped down from board.
  • Stoner is Entrepreneur Partner at MPM BioImpact; previously interim CEO at Semma Therapeutics.
  • She also founded Rhythm Pharmaceuticals, serving as chief medical officer and chief development officer; earlier led global clinical development operations at Merck Research Laboratories.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. iBio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605080715PRIMZONEFULLFEED9716270) on May 08, 2026, and is solely responsible for the information contained therein.

Contact Us

Contact Number :+852 3852 8500
Monday 7:00 AM - Saturday 9:00 AM (HKT)
Service Email :service@webull.hk
Online Support: Monday - Friday: 9:00 - 16:00; 22:30 - 5:00 (HKT)
Business Cooperation :marketinghk@webull.hk
Risk Disclosure: The content of this page is not an investment advice and does not constitute any offer or solicitation to offer or recommendation of any investment product. It is for general purposes only and does not take into account your individual needs, investment objectives and specific financial circumstances. All investments involve risk and the past performance of securities, or financial products does not guarantee future results or returns. Keep in mind that while diversification may help spread risk it does not assure a profit, or protect against loss, in a down market. There is always the potential of losing money when you invest in securities, or other financial products. Investors should consider their investment objectives and risks carefully before investing. For more details, please refer to risk disclosure.
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.
Language

English

©2026 Webull Securities Limited. All rights reserved.